Enzene Expands New Jersey Facility to Boost Next-Gen Biomanufacturing
To meet growing demand for advanced, domestic biomanufacturing capabilities, Enzene Biosciences is scaling up its soon-to-launch New Jersey facility to 80,000 square feet and integrating its proprietary continuous manufacturing platform.
End-to-end CDMO, Enzene Biosciences has announced the expansion of its soon-to-open biologics manufacturing facility in Hopewell, near Princeton, N.J. Ahead of its official launch, the facility’s capacity will increase further from 54,000 to 80,000 square feet, featuring drug substance manufacturing suites, laboratories, storage, dispensing, and warehousing capabilities (1).
The new facility will utilize the company’s modular EnzeneX 2.0 platform, designed to support clinical phase good manufacturing practice (GMP) supply starting from as low as 30 liters, featuring flexible bioreactor capacity to enable scale-on and scale-out expansion — adapting to meet diverse production demands.
“We will officially open our site later this year but are already producing non-GMP batches and seeing strong demand from U.S.-based small- and medium-sized innovators as we look ahead to GMP readiness,” commented Norm Stoffregen, SVP and site head at Hopewell, in a company press release (1). “With construction already well advanced, it made sense to seize the opportunity to add to the 54,000 square feet we had already planned, so that we could include additional capacity, larger dedicated quality control and development laboratories, and the space we will need for materials and finished goods.”
The company aims to transform the traditional biologics manufacturing landscape with its patented EnzeneX platform, which features Fully-Connected Continuous Manufacturing (FCCM) technology validated for commercial biologics. Unlike conventional batch processing, the platform enables an end-to-end continuous manufacturing process, facilitating uninterrupted production and rapid volume scaling to meet the evolving demands of the biomanufacturing sector.
This expansion strategy aligns with the accelerating growth of the biopharma sector. Recent market projections estimate the global digital biomanufacturing sector will grow from USD 2 billion this year to USD 12.3 billion by 2035 (2), with broader next-generation biomanufacturing forecast to exceed USD 44 billion by 2035 — driven by advances in automation, continuous processing, and rising demand for biologics and cell-based therapies (3).
While the biopharma industry is expanding rapidly, it also faces significant operational challenges — including high capital costs, persistent supply chain disruptions, and global uncertainties. Enzene aims to address these pressures by providing cutting-edge facilities and technical expertise, offering vital support to biotech companies striving to bring innovative therapies to market.
The expansion of biomanufacturing facilities, such as Enzene’s, not only alleviates operational pressures for individual companies but also advances broader national priorities. As the U.S. moves to bolster domestic biomanufacturing capacity in line with recent policy initiatives, such investments mark a meaningful step forward to support the growth of the country’s biotech sector.
References
Enzene. Ahead of Opening, Enzene Expands Scope for Biomanufacturing at New Jersey Site. Press Release, June 16, 2025.
Research and Markets. Digital Biomanufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Technology, Deployment Options, Type of Biologics and Key Geographical Regions. Report, February 2025.
Future Market Insights. Next-Generation Biomanufacturing Market — Trends, Innovations & Forecast 2025 to 2035. Report, April 16, 2025.